Damona Pharmaceuticals
damonapharma.com
Actively hiring
Medical AI
Neurology & CNS Therapeutics
Health Care
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Team
201-500
employees, estimated range
Backers
2
Angelini Ventures, Lumira Ventures
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
Backed byfrom the funds' portfolios and accelerator catalogs
Angelini Ventures 
Lumira Ventures Similar startupsby what they do, their industry and backers
Lario Therapeutics are developing first-in-class disease modifying treatments for severe neurological disorders. Precision Neuroscience…
Pioneering a New Era of Precision Medicines to Restore Brain Health and Wellbeing.
Developing transformative medicines for neurological and mental health disorders.
Draupnir Bio is developing new innovative therapies for patients.
We’re building a pipeline of next-generation therapeutics focused on broadening the treatment paradigm for migraine and other headache…
Biomia rationally engineers nature-inspired novel small molecule therapeutics to treat CNS disorders.
News
Damona Announces Publication of Preclinical Proof-of-Concept Data for DPX-101 (GL-II-73) Demonstrating Symptomatic and Disease-Modifying Potential for the Treatment of Cognitive Deficits in Alzheimer's Disease
- Small molecule DPX-101 has the potential to be the first disease-modifying therapy to reverse cognitive deficits such as memory loss in Alzheimer's disease - - Company plans to initiate Phase 1 clinical trial in first half of 2025 - TORONTO, February 4,
Read more
Report
Damona Pharmaceuticals Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of DPX-101, a Positive Allosteric Modulator Targeting the α5-GABA-A Receptor Subtype Selectively, with Broad Therapeutic Potential to Treat Cognitive Deficits Across Brain Disorders
- In preclinical models, small molecule DPX-101 demonstrated highly selective target activation and expected electrophysiological effects as well as improved cognitive performance in behavioral tests of frontal cortex and hippocampal functions - TORONTO,
Read more
Report
Damona Pharmaceuticals Appoints John Reilly as Chief Executive Officer
TORONTO, June 13, 2023- Damona Pharmaceuticals, a preclinical biopharmaceutical company focused on the discovery and development of first-in-class small molecules for the treatment and prevention of cognitive symptoms associated with brain disorders and a
Read more
Report
Damona Pharmaceuticals Raises US$5.5 Million Seed Stage Financing to Advance Lead Molecule Development to Treat Cognitive Deficits Associated with Depression and Diseases of Aging
TORONTO, September 26, 2022- Damona Pharmaceuticals today announced the closing of a seed stage financing round to support the development of its lead therapeutic for the treatment of cognitive symptoms associated with depression and diseases of aging. Th
Read more
Report